Risk of coronary artery disease in individuals infected with human immunodeficiency virus  by Vilela, Felippe Dantas et al.
O
R
IG
IN
A
L 
 
A
R
TI
CL
E
521
Risk of coronary artery disease in individuals infected 
with human immunodeficiency virus
Authors
Felippe Dantas Vilela1
Andrea Rocha de 
Lorenzo2
Bernardo Rangel Tura3
Giovanna Ianini 
Ferraiuoli4
Marcelo Hadlich1
Marcelo Viana de Lima 
Barros5
Ana Beatriz Ribeiro Lima6
Vanderson Meirelles7
1Postgraduate in 
Cardiology, Instituto 
Nacional de Cardiologia, 
RJ, Brazil
2PhD in Cardiology, 
Universidade Federal do 
Rio de Janeiro (UFRJ), RJ, 
Brazil 
3PhD in Biostatistics, UFRJ, 
RJ, Brazil 
4Professor, Instituto 
Nacional de Cardiologia, 
RJ, Brazil
5Nutritionist, Instituto 
Nacional de Cardiologia, 
RJ, Brazil
6Social Worker, Instituto 
Nacional de Cardiologia, 
RJ, Brazil 
7Physician, Instituto 
Nacional de Cardiologia, 
RJ, Brazil
Submitted on: 02/15/2011
Approved on: 06/27/2011 
Correspondence to: 
Felippe Dantas Vilela
Departamento de 
Pesquisa Clínica
Rua das Laranjeiras, 
374/5o – Laranjeiras
22240-006
Rio de Janeiro, RJ
Brazil
felippevilela@gmail.com
We declare no conflict of 
interest.
©2011 Elsevier Editora Ltda.  
ABSTRACT
Current treatment for human immunodeficiency virus (HIV) infection has improved survival and 
allowed infected patients to develop atherosclerotic coronary artery disease (CAD). Specific strate-
gies to reduce cardiovascular risk in the infected population have not been developed. It is neces-
sary to know the magnitude of cardiovascular risk in this population. Objectives: This study aimed 
to assess cardiovascular risk using a well-known clinical score and to investigate coronary artery 
calcium scoring (CACS) in this population. Methods: This was a cross-sectional study. Adults with 
HIV infection were studied. Demographic, clinical and anthropometric data, serum glucose and 
lipids were obtained. Cardiovascular risk was calculated through Framingham risk score (FRS) 
and CACS. Categorical variables were compared by Chi-square or Fisher’s exact test, and continuous 
variables were analyzed by Student t test or Mann-Whitney test. An analysis of concordance between 
FRS and CACS was performed using kappa statistic. Results: Forty patients, aged 45.9 ± 8.1 years, 
were studied. Age of risk for CAD were found in 30.0%, hypertension in 55.0%, diabetes in 10.0%, 
smoking in 35.0%, dyslipidemia in 67.5% and family history of CAD in 57.5%. Altered levels of total 
cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were found in 30.0%, 25.0% and 
82.5%, respectively. HDL-cholesterol and triglycerides were altered more frequently among protease 
inhibitors users. The FRS classified the risk as low for 72.5%, moderate for 25.0%, and high for 2.5%. 
CACS > 0 was found in 32.5% of the patients, in 67.5% the score was low, in 17.5% moderate, and in 
15.0% high. Concordance between FRS and CACS showed a kappa = 0.435. Conclusions: There is a 
high prevalence of risk factors for CAD in the studied population, with dyslipidemia being the most 
frequent. HDL-cholesterol and triglycerides were the most frequently altered factors and were asso-
ciated with the use of protease inhibitors. Risk assessed by the FRS was low in most cases. CACS > 0 
was found in 32.5%, demonstrating the need to re-evaluate the strategies for assessing cardiovascular 
risk in the HIV-infected population.
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INTRODUCTION
Infection with human immunodeficiency vi-
rus (HIV) is a public health problem world-
wide. In 2009, the United Nations estimated 
that worldwide 33.3 million people were in-
fected with HIV, being 1.4 million in South 
and Central Americas.1 In Brazil, updated data 
up to June 2010 accounted for 592,914 cases 
of acquired immunodeficiency syndrome 
(AIDS) reported since 1980, with 38,538 new 
cases reported in 2009.2,3 Public expendi-
tures with hospitalizations and complications 
due to AIDS in Brazil amounted to about 
8.2 million dollars in 2008 only, confirming the 
magnitude of the problem.3-5
Since 1996, with the advent of new 
antiretroviral therapies (ART), there have been 
significant gains in the fight against HIV infec-
tion, with increased life expectancy of these 
patients.4-6 This allowed, on the other hand, 
individuals with HIV infection to develop 
chronic diseases common to the general 
population, among which atherosclerotic car-
diovascular disease (ACVD), more specifically 
represented by atherosclerotic coronary artery 
disease (CAD), started to be highlighted. In 
the mid-90s, there was emphasis on reports of 
myocardial infarction (MI) in young patients 
infected with HIV and the possible associa-
tion between HIV infection and increased risk 
of CAD.5-7 Subsequent studies confirmed an Este é um artigo Open Access sob
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increased incidence of CAD in these individuals and over 
time, CAD has become a major cause of morbidity and mor-
tality in this population.6-9 
In the general population, the “IV Brazilian Guidelines 
on Dyslipidemia and Atherosclerosis Prevention” of the 
Brazilian Society of Cardiology recommends the use of 
stratification of cardiovascular risk and sets lipid targets 
for prevention and treatment of atherosclerosis.8 For that 
purpose, the use of the Framingham Risk Score (FRS) is 
indicated. The coronary artery calcium scoring (CACS), 
obtained through computed tomography, is considered an 
aggravating risk factor for CAD when the individual’s per-
centile adjusted for age and sex is > 75%.8,9 
In these guidelines some recommendations are proposed 
for special groups, such as individuals with HIV infection, for 
whom the risk assessment for CAD through the FRS and lipid 
profile is suggested.8 The “Recommendations for Antiretroviral 
Therapy in Adults Infected with HIV: 2008” also recommend 
that patients with HIV infection should be evaluated in order 
to identify the degree of cardiovascular risk. The approach is 
again based on the FRS, respecting some specific characteris-
tics of this group, such as the use of protease inhibitors (PI).10 
In this population, the use of complementary examinations is 
suggested, including imaging assessment such as CACS as an 
attempt to achieve better cardiovascular risk stratification.10  
 
MATERIAL AND METHODS
We studied HIV positive individuals over 18 years of age re-
ceiving care at specialized centers for treating HIV-infected 
patients, who presented no cardiovascular symptoms or his-
tory of CAD. By that it is understood: (I) myocardial infarc-
tion documented in hospital records or by clinical history 
associated with diagnostic methods; (II) stable or unstable 
angina, documented in hospital records, medical report or 
classical clinical history; (III) asymptomatic ischemic heart 
disease, but with coronary angiography showing a lesion 
> 50% in one or more coronary arteries or cardiac imaging 
assessment documenting ischemic alterations; (IV) previous 
CABG surgery; (V) prior coronary angioplasty; (VI) docu-
mented cerebrovascular accident; (VII) aortic aneurysmal 
disease or aortic stenosis; (VIII) peripheral artery disease 
documented by imaging method.
All patients who agreed to participate were seen by a 
multidisciplinary team consisting of cardiologists, social 
worker and nutritionist. Demographic, clinical, and anthro-
pometric data were obtained, including traditional risk fac-
tors for cardiovascular disease11-13 [age (≥ 45 years for men 
and ≥ 55 years for women), smoking (current smoking or 
stopped within the past 30 days), family history of early CAD 
(myocardial infarction or death from CAD of first-degree 
relatives, if male aged < 55 years and females aged < 65 
years), systemic arterial hypertension (SAH with previous 
diagnosis and/or use of antihypertensive medication), dys-
lipidemia (previous diagnosis and/or medication to reduce 
lipid levels) and diabetes mellitus (DM, with prior diagno-
sis and/or medication to reduce blood glucose)], current 
ART and PI use, body mass index (BMI, calculated as the 
ratio between the weight in kilograms and squared height 
in meters and considered normal from 18.5 to 24.9 kg/m2, 
overweight 25.0 to 29.9 kg/m2 and obesity ≥ 30.0 kg/m2);14,15 
abdominal circumference (AC, measured in cm, at the 
umbilicus and considered abnormal when > 102 cm in 
men and > 88 cm in women15-17), systemic blood pressure 
measurements at rest, with blood pressure considered to 
be altered when systolic blood pressure (SBP) levels were 
≥ 140 mmHg or if diastolic blood pressure (DBP) levels 
were ≥ 90 mmHg.18
All patients underwent glucose, triglycerides, HDL-
cholesterol, LDL-cholesterol and total cholesterol (TC) 
measurements after a 12-hour fasting period. For female 
patients of childbearing age, a qualitative beta-human cho-
rionic gonadotropin (beta-HCG) was also performed, due 
to the subsequent performance of the CT scan, which in-
volves radiation emission.
Serum glucose, TC, LDL-cholesterol and triglycerides 
were considered abnormal if, respectively, greater than 
100 mg/dL,19 200 mg/dL, 100 mg/dL and 150 mg/dL11; 
HDL-cholesterol was considered low when less than 
40 mg/dL and altered, according to sex, when < 45 mg/dL 
in men and < 55 mg/dL in women.20
The CT scan was performed in a 64-detector CT scan-
ner (Somatom Sensation 64, Siemens) within one week af-
ter the collection of laboratory tests. The Agatston score21,22 
was used in order to measure CACS,23-25 and percentiles 
were generated according to age and sex.24,26 The risk was 
categorized as “low” when there was no calcium in the cor-
onary arteries (CACS = 0),27 “moderate” when the CACS 
was less than or equal to the third quartile (75th percen-
tile)28 for age and sex, and “high” when CACS was greater 
than the third quartile for age and sex.8,27,28  
The FRS was classified as “low” risk when the rate ob-
tained was < 10%, “moderate” when the percentage was 
≥ 10% and ≤ 20%, and “high” when > 20%.8,29,30 Vari-
ables with normal distribution were expressed as 
mean ± standard deviation, and the variables with other 
distributions were described as median and interquartile 
range. Categorical variables were compared by Chi-square 
or Fisher’s exact test, and continuous variables by Student t 
test or Mann-Whitney test. An analysis of agreement 
between the CACS and the FRS risk assessments was per-
formed using kappa statistic. The reclassification of risk by 
CACS and based on the FRS was calculated as the percent-
age of individuals who changed the classification by the 
CACS stratification. In all analyses, a p value < 0.05 was 
considered significant. The statistical program used was R, 
version 2.12.1.31 
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RESULTS
We studied 40 patients, aged 45.9 ± 8.1 years, ranging from 31 
to 64 years. Only two (5%) were older than 60 years. Males ac-
counted for 52.5% of the sample. The demographic and clin-
ical characteristics of studied subjects are shown in Table 1. 
Two or more risk factors were found in 82.5% of patients and 
5.0% had five risk factors. The age of risk for CAD was ob-
served in 30.0% of individuals. A total of 27.5% individuals 
had altered blood pressure, and among individuals known 
to be hypertensive, 50% showed altered blood pressure. BMI 
was 25.3 ± 3.4 kg/m2, being classified as normal in 50.0% of 
subjects, 42.5% as overweight and obesity in 7.5%. The AC 
was 89.6 ± 9.7 cm in men, and in females, 88.3 ± 9.7 cm. 
There were significantly more women than men with altered 
AC (52.6% and 4.8% respectively, p = 0.001).  
Fasting blood glucose was 100.4 ± 13.8 mg/dL, and 
42.5% of patients had altered glucose levels (≥ 100 mg/dL). 
Regarding the lipid profile, TC was 188.7 ± 33.7 mg/dL 
(127-268 mg/dL), and 30.0% of patients had altered TC lev-
els (≥ 200 mg/dL). LDL-cholesterol was 112.5 ± 28.8 mg/dL 
(59-184 mg/dL) and was ≥ 130 mg/dL in 25.0% of the 
individuals. HDL-cholesterol was 39.7 ± 11.6 mg/dL 
(20-71 mg/dL), being 37.0 ± 11.0 mg/dL in men and 
42.6 ± 11.9 mg/dL in women. HDL cholesterol was consid-
ered abnormal for age and sex of individuals in 82.5% and 
< 40 mg/dL in 57.5%. Median triglyceride was 158.5 mg/dL 
(43-412 mg/dL, being the first quartile equal to 
104.0 mg/dL and the third quartile, 274.5 mg/dL). Triglyc-
erides were altered (≥ 150 mg/dL) in 52.5% of the sample. 
All patients were on ART, and 52.5% on PI. Table 2 
shows comparisons between patients who were on PI or not. 
No significant differences were detected, except for altered 
HDL-cholesterol adjusted for sex, which was more frequent 
in the group on PI (p = 0.040), and for altered triglycerides, 
which were more common in individuals who were on PI.
Assessment of cardiovascular risk through the FRS 
showed that the 10-year risk of MI or death due to CAD had 
a median of 4.0%, 2.0% in the first quartile and 10.0% in the 
third quartile. In this sample, 72.5% of patients were classi-
fied as low risk, 25.0% as moderate risk and 2.5% (only one 
individual) as high risk.  
The CACS had a median equal to zero, its value rang-
ing from zero to 632 points. Coronary calcification was 
found (CACS > 0) in 32.5% of individuals. Patient charac-
teristics according to the presence of coronary calcification 
are shown in Table 3. Subjects with coronary calcification 
were significantly older than patients without coronary cal-
cification (p = 0.015). However, other significantly different 
variables were not found between subjects with and without 
coronary calcification. 
According to the percentiles of CACS, 67.5% of patients 
had low risk, 17.5% had moderate risk, and 15.0% had high 
risk. The assessment of agreement between the FRS and 
CACS showed that 22 subjects (75.8%) with low FRS were 
also considered low risk by CACS, 4 (40.0%) of those with 
moderate risk by the FRS, had moderate risk by CACS and 
100% of those with high risk by the FRS had high risk by 
CACS, with a kappa value of 0.435 (Table 4). 
DISCUSSION 
Antiretroviral therapy has made HIV infection a chron-
ic condition, and although it is not curable, it is treatable. 
This fact has allowed the infected population to age and be 
subject to chronic diseases such as cardiovascular disease, 
especially CAD. Thus, it is extremely important to know the 
cardiovascular risk of these patients in order to plan pos-
sible interventions that might reduce this risk. The present 
study assessed patients with HIV infection in order to 
Table 1. Population characteristics 
Variable 
Age (years) 45.9 ± 8.1
Men 21 (52.5%)
SAH 22 (55.0%)
Type II diabetes  4 (10.0%)
Dyslipidemia 27 (67.5%)
Family history of early CAD  23 (57.5%)
Smoking 14 (35.0%)
Smoking load (pack/years)* 8.7*
AC- men (cm) 89.6 ± 9.7
AC- women (cm) 88.3 ± 9.7
BMI (kg/m2) 25.3 ± 3.4
SBP (mmHg) 124.2 ± 21.9
DBP (mmHg) 80.0 ± 10.9
Glucose (mg/dL) 100.4 ± 13.8
TC (mg/dL) 188.7 ± 33.7
LDL-cholesterol (mg/dL) 112.5 ± 28.8
HDL-cholesterol -men (mg/dL) 37.0 ± 11.0
HDL-cholesterol- women (mg/dl) 42.6 ± 11.9
Triglycerides (mg/dL) 158.5*
FRS (%) 4.0*
CACS 0.0*
Protease inhibitor use  21 (52.5%)
*median; SAH, systemic arterial hypertension; CAD, coronary 
artery disease; AC, abdominal circumference; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, 
high-density lipoprotein; FRS, Framingham Risk Score.
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Table 2. Comparisons according to the use of protease inhibitors
 With use Without use p-value 
 n = 21 (52.5%) n = 19 (47.5%)
AC (cm) 90.4 ± 11.2 87.4 ± 7.5 0.336
BMI (kg/m2) 25.9 ± 3.9 24.6 ± 2.8 0.248
Glucose (mg/dL) 102.2 ± 12.7 98.5 ± 14.9 0.404
TC (mg/dL) 192.2 ± 27.9 184.7 ± 39.5 0.493
Altered TC 38.1% 21.1% 0.240
LDL-cholesterol (mg/dL) 112.1 ± 26.5 112.8 ± 31.8 0.936
LDL-cholesterol < 100 mg/dL 33.3% 26.3% 0.629
HDL-cholesterol (mg/dL) 38.7 ± 8.8 40.7 ± 14.3 0.581
HDL-cholesterol < 40 mg/dL 57.1% 57.9% 0.962
Altered HDL-cholesterol  95.2% 68.4% 0.040
Triglycerides (mg/dL) 219.0* 130.0* 0.040
Triglycerides ≥ 150 mg/dL 71.4% 31.6% 0.012
FRS (%) 4.0%* 3.0%* 0.375
CACS 0.0* 0.0* 0.782
Coronary calcification  33.3% 31.6% 0.906
Value expressed as percentages or mean ± standard deviation; *median; AC, abdominal circumference; IMC, body mass index; 
TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FRS, Framingham Risk Score; CACS, coronary 
artery calcium score.
Table 3. Comparison between patients with or without coronary calcification 
 With calcification  Without calcification p-value 
 n = 13 (32.5%) n = 27 (67.5%)
Age (years) 50.3 ± 7.3 43.8 ± 7.7 0.015
Men 9 (42.8%) 12 (57.1%) 0.141
SAH 8 (36.3%) 14 (63.6%) 0.564
Type II diabetes  2 (50.0%) 2 (50.0%) 0.392
Dyslipidemia 9 (33.3%) 18 (66.6%) 0.584
Family history of early CAD 8 (34.7%) 15 (65.2%) 0.720
Smoking 4 (28.5%) 10 (71.4%) 1.000
Smoking load (pack/years) 5.0* 15.7* 0.229
AC (cm) 90.5 ± 10.3 88.3 ± 9.3 0.506
BMI (kg/m2) 24.9 ± 3.1 25.5 ± 3.6 0.627
SBP (mmHg) 117.6 ± 17.3 127.4 ± 23.5 0.194
DBP (mmHg) 78.4 ± 8.7 80.7 ± 11.9 0.543
Glucose (mg/dL) 100.1 ± 14.0 100.1 ± 13.9 0.833
TC (mg/dL) 196.6 ± 32.2 184.8 ± 34.3 0.309
LDL-cholesterol (mg/dL) 108.4 ± 29.5 114.4 ± 28.8 0.546
HDL-cholesterol (mg/dL) 39.6 ± 12.1 39.7 ± 11.7 0.975
Triglycerides (mg/dL) 193.0* 140.0* 0.525
FRS (% in 10 years) 8.0%* 3.0%* 0.142
Protease inhibitor use  33.3% 66.6% 0.906
*median; SAH, systemic arterial hypertension; CAD, coronary artery disease; AC, abdominal circumference; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-
density lipoprotein, FRS, Framingham Risk Score.
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determine the prevalence of traditional cardiovascular 
risk factors, assessing the risk of CAD through previ-
ously validated clinical scores and investigate the use of 
CACS for the diagnosis of subclinical coronary athero-
sclerosis and as an additional method for risk stratifica-
tion in this population.
In this sample, the mean age was 45.9 ± 8.1 years 
and only 30% were at the risk age. Therefore, it can be 
considered a young population for the development 
of CAD, but comparable to other studies of popula-
tions with HIV.6,30-33 However, a high proportion of 
patients (82.5%) had two or more traditional risk factors, 
highlighting the importance of proper stratification of 
cardiovascular risk in this group. SAH was present in 
55% of patients, being more frequent than in other stud-
ies, which showed prevalence rates of 35% to 41%34,35 
and 27.5% of the patients had altered blood pressure 
levels. These findings are similar to those found in the 
general Brazilian population, in which the levels of hy-
pertension control are still suboptimal,18,36 indicating 
the need for greater attention to blood pressure control 
in the HIV-infected population.18
Prevalence of smoking among HIV-infected patients 
of 47% to 71% has been reported, much more elevated 
than in the general population.34,37 The prevalence ob-
served in our sample was 35% lower than the rates cited 
above, but still twice the 17.5% prevalence of the Brazil-
ian population in 2008.38 Dyslipidemia was the most fre-
quent risk factor found in 67.5% of individuals. In the 
study by Cahn et al.,39 the prevalence of dyslipidemia in 
the Brazilian population with HIV infection was 57.3%.
The levels of TC and LDL-cholesterol were slight-
ly higher than the percentage described in the study 
by Kingsley et al.40 HDL-cholesterol levels were altered in 
the majority of the studied population (82.5%). The study 
by Kingsley et al.40 identified only 40% of individuals with 
low HDL-cholesterol, whereas in our population, 57.5% 
were identified at this level. However, it is noteworthy that 
these authors did not take into account the adjustment of 
HDL-cholesterol according to sex. As for triglycerides, our 
results are also similar to those previously described (38%).40 
In this population, 52.5% of patients were using PI, 
which is similar to another Brazilian study.39 No signifi-
cant differences in levels of TC and LDL-cholesterol were 
found in our sample among individuals using PI or not, 
similarly to other studies, i.e., minor alterations in these 
lipid fractions.41-43 However, HDL-cholesterol, corrected 
for age and sex, was significantly more frequent among 
patients using PI. This difference has been reported in the 
literature, associated with risk of MI.44 It was also possible 
to demonstrate the association between the use of PI and 
increased levels of triglycerides, and the median in the 
group that used PI was 219 mg/dL, compared to 130 mg/dL 
in the group that did not use PI. This association has also 
been previously described.45  
Risk assessment through the FRS showed that the pop-
ulation of this sample had low risk (FRS median of 4.0% 
and the third quartile of 10.0%), which can be explained 
by their age, predominantly young. Notably, one fourth of 
individuals were classified according to the FRS as having 
moderate risk, and 2.5% as having high risk. A significant 
proportion of individuals with moderate risk underscores 
the importance of a refinement of risk stratification of this 
population in order to establish the best treatment and re-
duce the incidence of adverse cardiovascular events.
Screening for subclinical atherosclerosis through 
CACS showed that about one third of patients had cor-
onary calcifications, an indicator of the presence of 
atherosclerosis. Studies carried out in the general popu-
lation have shown that at the age range of 40-45 years, 
there is a prevalence of coronary calcification of 13.3% 
to 21%.46,47 The frequency of calcification found in this 
sample was similar to the study by Crum-Cianflone et 
al.48 among individuals with HIV infection, in which 34% 
of patients showed calcification in the coronary arteries. 
Patients with calcification in the coronary arteries were 
significantly older than those without calcification, which 
has been shown in other studies of patients with and with-
out HIV infection.32,40,47,49 Although other studies have 
already reported an association between coronary calcifi-
cation in individuals with HIV and other variables (SBP, 
triglycerides, TC, smoking, FH of CAD, dyslipidemia)30,40 
these associations were not found in our population, pos-
sibly due to the small sample size. 
The agreement between the risk stratification by FRS 
and the CACS showed a kappa of 0.435. In this study, we 
did not have access to the clinical follow-up of patients, and 
therefore could not make any inference regarding the accu-
racy of these two forms of risk stratification to predict the 
occurrence of events. Although it was not possible to estab-
lish the best score for risk prediction in this population, it 
Table 4. Agreement between risks assessed by FRS 
and CACS
   CACS  Total
  Low Moderate High 
FRS 
 Low  22 3 4 29
 Moderate 5 4 1 10
 High  0 0 1 1
Total  27 7 6 40
FRS, Framingham Risk Score; CACS, coronary artery calcium 
scoring. 
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was possible to verify the frequency of modifications in risk 
classes defined by the FRS provided by CACS. The reclas-
sification of risk occurred in 32.5% of individuals, and from 
the category of low risk by FRS, 24% had their risk increased 
(10.3% to moderate risk and 13.7% to high risk). From the 
category of moderate risk (the most widely described as 
the main indication for refinement of risk assessment), 10% 
had their risk increased and 50% had the risk decreased.  
The effect of CACS on moderate-risk individuals 
by the FRS was consistent with published data, which 
showed a higher frequency of reclassifications exactly in 
this category.50-52 This capacity of CACS makes it attrac-
tive to refine risk stratification in the HIV-infected pop-
ulation. For individuals considered high risk by CACS, 
the therapeutic approach would possibly be changed.8,11  
CONCLUSIONS
One of the limitations of the study was the unavailabil-
ity of data like the time of HAART, use of PI and HIV 
infection, which may be correlated with the occurrence 
of CAD. Larger studies with long-term clinical follow-
up are necessary to confirm the findings and allow ob-
taining a precise risk score, specific for the needs of this 
population. 
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